Journal of the American Society of Hypertension
Volume 3, Issue 4 , Pages 260-266 , July 2009

C-reactive protein among community-dwelling hypertensives on single-agent antihypertensive treatment

  • Tibor Fulop, MD

      Affiliations

    • Internal Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA
    • Corresponding Author InformationCorresponding author: Tibor Fulop, MD, University of Mississippi Medical Center, Department of Internal Medicine, Division of Nephrology, 2500 North State Street, Jackson, Mississippi 39216. Tel: 601-984-5670; fax: 601-984-5765.
    • ,
  • Andrew D. Rule, MD

      Affiliations

    • Department of Internal Medicine, Mayo Clinic Foundation, Rochester, Minnesota, USA
    • ,
  • Darren W. Schmidt, MD

      Affiliations

    • Internal Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA
    • ,
  • Heather J. Wiste, BA

      Affiliations

    • Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    • ,
  • Kent R. Bailey, PhD

      Affiliations

    • Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    • ,
  • Iftikhar J. Kullo, MD

      Affiliations

    • Department of Internal Medicine, Mayo Clinic Foundation, Rochester, Minnesota, USA
    • ,
  • Gary L. Schwartz, MD

      Affiliations

    • Department of Internal Medicine, Mayo Clinic Foundation, Rochester, Minnesota, USA
    • ,
  • Thomas H. Mosley Jr., PhD

      Affiliations

    • Internal Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA
    • ,
  • Eric Boerwinkle, PhD

      Affiliations

    • Institute of Molecular Medicine and Human Genetics Center, Houston, Texas, USA
    • ,
  • Stephen T. Turner, MD

      Affiliations

    • Department of Internal Medicine, Mayo Clinic Foundation, Rochester, Minnesota, USA

Received 14 February 2009 ,Accepted 27 March 2009.

References 

  1. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New Engl J Med. 2000;342:836–843
  2. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation. 2002;105:2595–2599
  3. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al. Inflammatory markers and the risk of coronary heart disease in men and women. New Engl J Med. 2004;51:2599–2610
  4. Ford ES, Giles WH. Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey. Arterioscl Thromb Vasc Biol. 2000;20:1052–1056
  5. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005;293:1737–1745
  6. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh , et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. New Engl J Med. 2006;355:2631–2639
  7. Bautista LE, Lopez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension?. J Hypertension. 2001;19:857–861
  8. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290:2945–2951
  9. Schillaci G, Pirro M, Gemelli F, Pasqualini L, Vaudo G, Marchesi S, et al. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J Hypertension. 2003;21:1841–1846
  10. Kullo IJ, Seward JB, Bailey KR, Bielak LF, Grossardt BR, Sheedy PF, et al. C-reactive protein is related to arterial wave reflection and stiffness in asymptomatic subjects from the community. Am J Hypertens. 2005;18:1123–1129
  11. Conen D, Zeller A, Pfisterer M, Martina B. Usefulness of B-type natriuretic peptide and C-reactive protein in predicting the presence or absence of left ventricular hypertrophy in patients with systemic hypertension. Am J Card. 2006;97:249–252
  12. Manabe S, Okura T, Watanabe S, Fukuoka T, Higaki J. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharm. 2005;46:735–739
  13. Amar J, Ruidavets JB, Peyrieux JC, Mallion JM, Ferrieres J, Safar ME, et al. C-reactive protein elevation predicts pulse pressure reduction in hypertensive subjects. Hypertension. 2005;46:151–155
  14. Fliser D, Buchholz K, Haller H. For the European trial on olmesartan and pravastatin in inflammation and atherosclerosis (EUTOPIA) investigators. Anti-inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110:1103–1107
  15. Schram MT, van Ittersum FJ, Spoelstra-de Man A, van Dijk RA, Schalkwijk CG, Ijzerman RG, et al. Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. J Hum Hypertens. 2005;19:429–437
  16. Palmas W, Ma S, Psaty B, Goff DC, Darwin C, Barr RG. Antihypertensive Medications and C-reactive Protein in the Multi-Ethnic Study of Atherosclerosis. Am J Hypertens. 2007;20:233–241
  17. FBPP Investigators. Multi-center genetic study of hypertension: the Family Blood Pressure Program (FBPP). Hypertension. 2002;39:3–9
  18. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol. 1989;129:687–702
  19. Melton LJ. History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996;71:266–274
  20. Keevil BG, Nicholls SP, Kilpatrick ES. Evaluation of a latex-enhanced immunoturbidimetric assay for measuring low concentrations of C-reactive protein. Ann Clin Biochem. 1998;35:671–673
  21. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41–46
  22. Godefroi R, Klementowicz P, Pepler C, Lewis B, McDonough K, Goldberg RJ. Levels of, and factors associated with, C-reactive protein in employees attending a company-sponsored cardiac screening program. Cardiology. 2005;103:180–184
  23. Rogowski O, Shapira I, Shirom A, Melamed S, Toker S, Berliner S. Heart rate and microinflammation in men: a relevant atherothrombotic link. Heart. 2007;93:940–944
  24. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Centers for Disease Control and Prevention. American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511
  25. Ridker P, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Eng J Med. 1997;336:973–979
  26. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–1397
  27. Pankow JS, Folsom AR, Cushman M, Borecki IB, Hopkins PN, Eckfeldt JH, et al. Familial and genetic determinants of systemic markers of inflammation: the NHLBI Family Heart Study. Atherosclerosis. 2001;154:681–689
  28. Ding K, Feng D, de Andrade M, Mosley TH, Turner ST, Boerwinkle E, et al. Genomic regions that influence plasma levels of inflammatory markers in hypertensive sibships. J Hum Hypertens. 2008;22:102–110
  29. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem. 2001;47:444–450

 This study was supported by the National Institute of Health Grants Nos. U01 HL 54464, U01 HL 54457, U01 HL 54463, U01 HL 54481, and R01 AR 30582 and clinical revenue support of the University of Mississippi Medical Center.

 Conflict of interest: none.

PII: S1933-1711(09)00044-8

doi: 10.1016/j.jash.2009.03.003

Journal of the American Society of Hypertension
Volume 3, Issue 4 , Pages 260-266 , July 2009

Article Tools